# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
FDA approves Adaptimmune Therapeutics' Tecelra for unresectable or metastatic synovial sarcoma, a rare cancer near large jo...
Galapagos (NASDAQ:GLPG) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $(0.04) by ...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next gener...
BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product ...
Results from our continuing operationsTotal operating loss from continuing operations for the three months ended 31 March 2024 ...
Morgan Stanley analyst Judah Frommer maintains Galapagos (NASDAQ:GLPG) with a Equal-Weight and maintains $38 price target.
Two oral presentations and one poster on encore preliminary data from Phase 1/2 CD19 CAR-T studies in non-Hodgkin lymphoma (NHL...